The Gene Therapy For Retinal Diseases Market is expected to grow at an 8.0 % CAGR during the forecast period for 2023-2031.
Gene therapy states a method of announcing foreign DNA constructs into host cells in demand to treat various medical conditions, including retinal diseases. Gene therapy has an increasing research potential, mainly in the arena of retinal and ophthalmic diseases. The main features of the eye include convenience in terms of surgical interventions and injections and fitted blood-ocular barriers that bar other organs from undesirable contamination. The high potential of gene therapy to treat ocular diseases is boosting the demand for the market globally. Additionally, the approval of the first gene therapy for retinal diseases in 2017 is expected to increase the demand in the coming years.
The presence of several drugs under clinical trials and their positive results are expected to generate immense opportunities for market growth over the forecast period. The evidence of the use of the gene as a medicine has come a long way and establishes its position in treating retinal disease. Certainly, with only limited availability of treatment options for retinal diseases, gene therapy has been established safe, feasible, and effective and could lead to robust effects after a single injection. Moreover, growing strategic partnerships and acquisitions among the key players operating in the market are expected to significantly propel market growth. However, the high cost associated with gene therapy may affect the growth of gene therapy in the retinal disease market. However, growing demand for modified and effective treatment and rising research funding globally is estimated to drive the market growth substantially during the estimated time frame.
The Global Gene Therapy for Retinal Diseases Market is segmented on the basis of indication, and region. Based on the indication, the market is divided into Choroideremia (CHM), Leber congenital amaurosis, Leber’s hereditary optic neuropathy, X-linked retinitis pigmentosa, and Other Indication. Based on the region, the market is studied across North America, Asia-Pacific, Europe, and the Rest of the World. North America accounted for the significant share in the gene therapy for retinal disease market, followed by Europe. A large number of research laboratories and biopharmaceutical companies operating in the market are contributing towards the high share of the region in the global market. Additionally, well-established healthcare infrastructure in the U.S. and the high adoption of advanced technologies for treatment are propelling the growth of U.S. gene therapy for the retinal diseases market.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 8.0 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Applied Genetic Technologies Corporation, Adverum Biotechnologies, ProQR Therapeutics, MeiraGTx Limited., Oxford BioMedica, Horama S.A., Gensight Biologics, Regenxbio Inc., Spark Therapeutics, Inc., Genzyme (Sanofi), Novartis Pharmaceuticals, Nightstar Therapeutics (Biogen), Hemera Biosciences, Allergan, and others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene Therapy for Retinal Diseases Market Snapshot
Chapter 4. Global Gene Therapy for Retinal Diseases Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Epidemiology: Incidence Prevalence Analysis 2019
4.6.1. Choroideremia (CHM)
4.6.2. Leber congenital amaurosis
4.6.3. Leber’s hereditary optic neuropathy
4.6.4. Retinitis pigmentosa
4.6.5. X-linked retinitis pigmentosa
4.6.6. X-linked retinoschisis
4.6.7. Usher syndrome type 1B
4.6.8. Stargardt disease
4.6.9. Achromatopsia
4.6.10. Neovascular/age-related macular degeneration
4.7. Clinical Trial/Pipeline Analysis
4.8. Industry Analysis – Porter’s Five Forces Analysis
4.9. Technology Advancement in Gene Therapy for Retinal Diseases Market
Chapter 5. Market Segmentation 1: Indication Estimates & Trend Analysis
5.1. Indication Type & Market Share, 2020 & 2030
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following Indication:
5.2.1. Choroideremia (CHM)
5.2.2. Leber congenital amaurosis
5.2.3. Leber’s hereditary optic neuropathy
5.2.4. Retinitis pigmentosa
5.2.5. X-linked retinitis pigmentosa
5.2.6. X-linked retinoschisis
5.2.7. Usher syndrome type 1B
5.2.8. Stargardt disease
5.2.9. Achromatopsia
5.2.10. Neovascular/age-related macular degeneration
5.2.11. Other Indication
Chapter 6. Gene Therapy for Retinal Diseases Market Segmentation 3: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Gene Therapy for Retinal Diseases Market revenue (US$ Million) estimates and forecasts by Indication, 2020-2030
6.1.2. North America Gene Therapy for Retinal Diseases Market revenue (US$ Million) estimates and forecasts by country, 2020-2030
6.1.2.1. U.S.
6.1.2.2. Canada
6.2. Europe
6.2.1. Europe Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, 2020-2030
6.2.2. Europe Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, 2020-2030
6.2.2.1. Germany
6.2.2.2. Poland
6.2.2.3. France
6.2.2.4. Italy
6.2.2.5. Spain
6.2.2.6. UK
6.2.2.7. Rest of Europe
6.3. Asia Pacific
6.3.1. Asia Pacific Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, 2020-2030
6.3.2. Asia Pacific Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, 2020-2030
6.3.2.1. China
6.3.2.2. India
6.3.2.3. Japan
6.3.2.4. Australia
6.3.2.5. Rest of Asia Pacific
6.4. Latin America
6.4.1. Latin America Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, (US$ Million)
6.4.2. Latin America Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, (US$ Million) 2020-2030
6.4.2.1. Brazil
6.4.2.2. Rest of Latin America
6.5. MEA
6.5.1. MEA revenue Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, (US$ Million) 2020-2030
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Applied Genetic Technologies Corporation
7.2.2. Adverum Biotechnologies
7.2.3. ProQR Therapeutics
7.2.4. MeiraGTx Limited.
7.2.5. Oxford BioMedica
7.2.6. Horama S.A.
7.2.7. Gensight Biologics
7.2.8. Regenxbio Inc.
7.2.9. Spark Therapeutics, Inc.
7.2.10. Genzyme (Sanofi)
7.2.11. Novartis Pharmaceuticals
7.2.12. Nightstar Therapeutics (Biogen)
7.2.13. Hemera Biosciences
7.2.14. ViGeneron GmbH
7.2.15. Allergan
7.2.16. Eyevensys
7.2.17. Clearside Biomedical
7.2.18. IVERIC bio, Inc.
7.2.19. Other Prominent Players
Global Gene Therapy for Retinal Diseases Market by Indication
Global Gene Therapy for Retinal Diseases Market Based on Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
